(Q51757887)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

metastatic adenocarcinoma

1 reference

adenocarcinoma of the lung

inferred from title

1 reference

Dae Ho Lee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Ji-Youn Han

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Sun Young Yu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Hyae Young Kim

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Byung-Ho Nam

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Eun Kyung Hong

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Heung Tae Kim

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Jin Soo Lee

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 November 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

Journal of Thoracic Oncology

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

965-971

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Second-line chemotherapy for non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Prognostic factors in lung cancer based on multivariate analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931642-7

7 January 2021

10.1016/S1556-0864(15)31642-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409980%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference